TNKase
Mar 10, 2025
Roche’s TNKase — First New Acute Ischemic Stroke Drug in Nearly 30 Years
For nearly three decades, Genentech has been the sole provider of an approved medication for acute stroke treatment. On 03 March 2025, the Roche subsidiary expanded its stroke treatment portfolio with FDA approval for TNKase (tenecteplase). TNKase (tenecteplase) is a thrombolytic, clot-dissolving tis...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
